Latest news with #Boehringer
Yahoo
6 days ago
- Business
- Yahoo
Boehringer Ingelheim and LEO Pharma Enter Partnership to Commercialize and Further Develop SPEVIGO® (spesolimab)
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma's six decades of dermatology expertise and Boehringer's global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations INGELHEIM, Germany & BALLERUP, Denmark, July 14, 2025--(BUSINESS WIRE)--GLOBAL RELEASE - NOT INTENDED FOR UK MEDIA Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO® (spesolimab). SPEVIGO® is an innovative, humanized, and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor - a key signaling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, including generalized pustular psoriasis (GPP).123 This partnership extends beyond GPP, with an opportunity to investigate the potential of spesolimab in additional skin conditions with high unmet medical need in which IL-36 is implicated. Under the terms of the agreement, LEO Pharma will be responsible for commercialization and further development of SPEVIGO® leveraging its global commercial platform within medical dermatology to raise disease awareness and secure access for patients with GPP. The addition of Boehringer Ingelheim's flagship dermatology product, SPEVIGO®, for the treatment of GPP, complements LEO Pharma's existing strategic dermatology portfolio and reinforces its long-standing commitment to delivering transformational medicines to patients. "We are immensely proud of what SPEVIGO® represents for people living with GPP and bringing innovation to this community of patients has been a powerful reflection of our purpose to transform lives," said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. "SPEVIGO® holds a significant promise, and ensuring it reaches its full potential requires continued focus, and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we've laid. We remain profoundly grateful to the patients, caregivers, and healthcare professionals who have walked this journey with us." "Skin diseases can profoundly impact people's lives - and at LEO Pharma, we are here to change that," said Christophe Bourdon, CEO of LEO Pharma. "Partnering to bring SPEVIGO® to more patients is more than a strategic step - it means the opportunity to help people living with GPP by addressing a disease with limited treatment options and aiming to improve their quality of life. We are inspired by Boehringer Ingelheim's pioneering efforts and thrilled to build on that foundation. Together, we have a powerful opportunity to expand access to innovative care and deliver meaningful progress for patients who have long been underserved." GPP is a rare, heterogeneous, and potentially life-threatening skin disease. It is characterized by the accumulation of neutrophils (a type of white blood cell) in the skin, leading to painful, sterile pustules across the body. The disease course varies, with some patients experiencing relapsing episodes with recurrent flares - often accompanied by fever, malaise, fatigue, and a risk of organ failure - while others endure persistent disease with intermittent flares.7891011 SPEVIGO® is available in more than 40 countries including the U.S., Japan, China, and most European countries to treat GPP flares in adults.4 It is the first approved treatment for GPP flares that specifically targets the IL-36 pathway and that has been evaluated in a statistically powered, randomized, placebo-controlled trial.5 Additionally, SPEVIGO® has also been approved for expanded indications in generalized pustular psoriasis in the EU, U.S. and China.6 SPEVIGO® is also under investigation for the treatment of other IL-36 mediated skin diseases. The transaction is anticipated to close in the second half of 2025, subject to merger control clearance, with Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties. July, 2025 About Spevigo SPEVIGO® is a novel, humanized, selective antibody that specifically blocks the activation of the IL-36R, a signalling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP. It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP.123 About generalized pustular psoriasis (GPP) GPP is a chronic, heterogenous, neutrophilic inflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment.78 GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems.89 GPP symptoms appear unpredictable and present on a continuum, which greatly impacts a patient's quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities, and finances.81011 About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serve close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit 1 Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402:1541–1551.2 Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11:e043666.3 Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431–2440.4 Record on file.5 Boehringer Ingelheim. Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial. 2023. (Accessed 22 July 2024).6 Boehringer Ingelheim. European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis. 2024. (Accessed 29 June 2025).7 Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:13–19.8 Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. J Eur Acad Dermatol Venereol. 2023;37:256–273.9 Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:21–29.10 Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–919.11 Reisner DV, Johnsson FD, Kotowsky N, et al. Impact of generalized pustular psoriasis from the perspective of people living with the condition: Results of an online survey. Am J Clin Dermatol. 2022;23:65–71. View source version on Contacts Boehringer Ingelheim Tereza Urbankova, Senior Media Relations ManagerE-Mail: press@ Phone Number: +49 (6132) 77-184817LEO Pharma Jeppe Ilkjær, MediaE-Mail: jeilk@ Phone Number: +45 3050 2014Christian Soerup Ryom, InvestorsE-Mail: chsoe@ Phone Number: +45 3089 9083 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
04-07-2025
- Business
- Reuters
Drugmaker Alchem hit with $576,000 EU fine for taking part in pharmaceutical cartel
BRUSSELS, July 4 (Reuters) - Drugmaker Alchem International and its Hong Kong subsidiary were fined a total of 489,000 euros ($576,000) for taking part in a pharmaceutical cartel, EU antitrust regulators said on Friday. The European Commission had imposed a total fine of 13.4 million euros on Alkaloids of Australia, Alkaloids Corp, Boehringer, Linnea and Transo-Pharm in 2023 for fixing the minimum price of an ingredient to produce the abdominal antispasmodic drug Buscopan and its generic versions. The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle. "Our investigation showed that Alchem, the only producer who chose not to settle, illegally coordinated prices and allocated quotas for more than 12 years," EU antitrust chief Teresa Ribera said in a statement. ($1 = 0.8490 euros)
Associated Press
24-06-2025
- Health
- Associated Press
Boehringer Ingelheim's 'Sailboat for Health' Brings Healthcare to Remote Greek Islands
We've all seen those idyllic scenes of picturesque Greek islands: fantastic fun in the sun on a hot summer's day. But what does it mean to live there in the cold and grey of winter? What happens when temporary healthcare facilities return to the mainland for the offseason? Particularly for those with a health condition that needs regular attention? For patients with diabetes, access to healthcare can be a daunting challenge. Boehringer Ingelheim Greece, alongside its partners, is addressing this issue with the 'Sailboat for Health' initiative. This floating medical facility embarks on annual voyages to deliver essential healthcare services to isolated islands. By providing screenings, treatments, and education, the Sailboat for Health aims to help enable islanders to manage their health without needing to leave the island. Since its inception, the initiative has supported about 50 islands, offering over 700 medical appointments in 2023 alone. With ongoing support from local NGOs and medical associations, Boehringer aims to help make a positive impact on the lives of those living on remote islands, ensuring they receive the care they need and deserve. Find out more and explore other stories on Imagine: our sustainability story hub, where we share our commitment to sustainability and what we are doing to create a positive impact for humans, animals and our planet.
Yahoo
10-06-2025
- Health
- Yahoo
Boehringer Ingelheim and Eko Health Inc. enter digital health collaboration to improve heart murmur detection in dogs
A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to life-extending cardiac care for dogs Ingelheim, Germany, and San Francisco, Calif., June 10, 2025 | Boehringer Ingelheim, a global leader in animal health, and Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, have entered a strategic collaboration agreement. This collaboration brings together Boehringer's depth in canine cardiology with Eko Health's powerful AI algorithms and digital stethoscopes – already trusted by healthcare professionals worldwide, with over 650,000 devices sold for use in human medicine. Leveraging their combined expertise, along with Boehringer's proprietary algorithm developed with support from leading veterinary cardiologists worldwide, the partnership aims to enhance the early detection and diagnosis of heart disease in dogs. A canine-specific detection algorithm will be made available to veterinarians through a purpose-built Eko mobile app launching in 2026. A heart murmur in dogs is an audible sound resulting from turbulent blood flow when cardiac valves fail to close properly, similar to the condition observed in humans. Heart murmurs are a very typical finding in canine myxomatous mitral valve disease (MMVD)1, a chronic and common heart condition that is a major cause of morbidity and mortality in dogs2 and affects approximately 10 to 15% of dogs in their lifetime.3 'As a longtime leader in canine cardiology, we know that early diagnosis of MMVD and consideration of early appropriate treatment are key to helping affected dogs live better and longer lives; explained Dr. Erich Schött, Head of Pet Therapeutics and Pet Vaccines at Boehringer Ingelheim. 'By collaborating with Eko Health, we look forward to simplifying and improving canine heart murmur detection so that more dogs and pet owners can have additional years of life to love. The innovative tool will give veterinarians the ability to hear, see and document the sounds of heart murmurs and to share it with the dog owners.' Regular veterinary check-ups are vital for maintaining optimal health in dogs, yet many dogs are not evaluated for potential heart murmurs. In a typical clinic visit, veterinarians rely on an analog stethoscope to detect murmurs—often in noisy environments and during time-constrained exams. This traditional method can miss subtle or early-stage murmurs, especially those that fall outside the range of human hearing. Through this partnership, Boehringer Ingelheim and Eko are equipping veterinarians with a simple, powerful tool to detect heart murmurs earlier and with greater confidence.'We're proud to partner with Boehringer Ingelheim to deliver AI-powered tools that meaningfully improve how veterinarians detect heart disease,' said Connor Landgraf, CEO and co-founder of Eko Health. 'By combining Boehringer's global leadership in animal health with Eko's unique ability to deliver advanced detection algorithms to the point of care, we can help millions of pets—and the families who love them—receive the life-extending care they Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at About Boehringer Ingelheim – Animal Health business Boehringer Ingelheim provides first-in-class innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at For more information, visit About Eko Health Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, with over 650,000 devices sold to clinicians globally, allows them to detect earlier and with higher accuracy, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $165 million in funding from ARTIS Ventures, DigiTx Partners, Double Point Ventures, EDBI, Highland Capital Partners, LG Technology Ventures, Mayo Clinic, Morningside Technology Ventures Limited, NTTVC, Questa Capital, and others. For more information, visit Hezzell M. Pathology and prognosis of canine myxomatous mitral valve disease. In pract.2018 Mar; 40 (S1): 3-6.2 Häggström, J et al. 'New insights into degenerative mitral valve disease in dogs.' Veterinary Clinics of North America: Small Animal Practice. 2004 vol 34, 5: 1209-1226. doi: 10.1016/ Keene, Bruce W et al. 'ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.' Journal of veterinary internal medicine vol. 33,3 (2019): 1127-1140. in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
26-05-2025
- Health
- Cision Canada
Empowering Canadians with type 2 diabetes: Program highlights the power of education and allied health Français
BURLINGTON, ON, May 26, 2025 /CNW/ - New outcomes from Boehringer Ingelheim Canada's Access for Health Education and Disease Management (AHEAD) program underscores the essential role that allied health professionals and disease management education play in the lives of Canadians living with type 2 diabetes (T2D). According to a 2025 survey, Boehringer's innovative national program, AHEAD, has helped patients become active partners in their care by improving their understanding and self-management of their own health conditions. "The program has been instrumental in enhancing patient education at our clinic. Having resources on-site, where patients are comfortable and familiar with the staff, has removed barriers to access and created a positive patient experience," said Dr. Matthew D'Mello, Community Family Physician at the Glazier Medical Clinic in Oshawa, Ontario. A survey of the participating allied healthcare professionals revealed that 97 per cent of respondents felt the AHEAD program addressed a specific gap or need, with patients reporting an 88 per cent improvement in their quality of life and a 92 per cent enhancement in disease management. AHEAD was implemented in over 70 primary and specialty care clinics across Canada for the duration of 2024, reaching about 3,200 patients. The program focused on optimizing disease management through guideline-directed medical therapy, seeking to improve health outcomes with the potential to reduce rehospitalization rates, and decrease emergency department visits. Educators offered culturally diverse, accessible support, allowing participants to receive care how and where it was most impactful for them. "I am grateful for the incredible opportunity provided by the AHEAD program. It has enabled me to educate patients about their diabetes focusing on self-management, setting realistic goals, identifying individual barriers, and offering solutions to positively impact their health journeys," said Mrudula Golla, a pharmacist and diabetes educator in Oshawa, Ontario "We are excited to see the implementation of the AHEAD program has succeeded in addressing the needs of people living with type 2 diabetes," says Dr. Rasha Eldesouky Abouelabbas, Vice President, Medical and Regulatory Affairs Boehringer Ingelheim Canada. "As a system collaborator, Boehringer is proud to continue investing in programs like AHEAD to address critical gaps in the healthcare system, making a meaningful impact in the lives of patients and the system as a whole." Boehringer Ingelheim (Canada) Ltd. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 500 people across Canada. Learn more at
